RAD 2025: Long-Term Data on Nemluvio ® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to#RAD #LongTerm #Data #Nemluvio #nemolizumab #Demonstrate #Favorable #Safety #Profile #Sustained #Increased #Improvements #Itch #Skin #Lesions #Patients #Atopic #Dermatitis